Dr. Anne Blackwood, CEO, Health Enterprise East (HEE), has been named as an outstanding female leader in the bioscience industry in BioBeat’s 2018 “50 Movers and Shakers in BioBusiness” report.
Now in its fifth year of publication, the annual BioBeat “50 Movers and Shakers in BioBusiness” report highlights the women who are shaping the bioscience industry from clinical to boardroom level. BioBeat is a collaborative innovation platform for healthcare entrepreneurs and leaders that brings together scientific and business expertise, for the ultimate benefit of innovative new treatments. The business leaders have been chosen thanks to their outstanding commitment to drive innovation and technological change within the UK biomedical community.
Anne has been recognised for her work in bioscience investment as the co-founder of Medovate, the incubator for development of medical technologies originating in the NHS, as well as for her dedication to supporting the commercialisation of medical innovations. She has also been applauded for her role in establishing the Medtech Accelerator to provide proof of concept funding for technologies that solve healthcare problems.
Dr. Anne Blackwood, CEO, HEE, commented: “It is an honour to be listed in this year’s BioBeat “50 Movers and Shakers in BioBusiness 2018”. Understanding the complex pathways and funding requirements needed to develop emerging new medical technologies is a key part of what we do at HEE. Without proper funding, pioneering technologies would not get past the initial crucial stages of development. We are passionate about paving the way for new innovative technologies to be used by the NHS and by helping to unlock investment for emerging businesses, we are helping ground-breaking products and devices be developed and brought to market faster, benefitting patients and staff and potentially saving lives.”